| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $277.0M | +54.8% |
| Cost of Revenue | $71.4M | -1.0% |
| R&D Expense | $93.8M | -8.9% |
| SG&A Expense | $72.7M | -0.1% |
| Operating Income | -$57.1M | +64.9% |
| Interest Expense | $11.8M | +1.7% |
| Pre-tax Income | -$59.5M | +62.7% |
| Income Tax | $0 | — |
| Net Income | -$59.5M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $70.5M | +47.1% |
| Accounts Receivable | $50.4M | +20.7% |
| Inventory | $9.8M | +16.4% |
| Current Assets | $300.2M | +5.8% |
| Total Assets | $512.7M | -4.9% |
| Current Liabilities | $89.9M | -8.3% |
| Long-term Debt | $126.6M | -4.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$46.0M | +51.7% |
| Capital Expenditures | $3.0M | -19.2% |
| Investing Cash Flow | $38.0M | -51.2% |
| Financing Cash Flow | $30.4M | — |
| Free Cash Flow | -$48.9M | +50.5% |
| +62.7% |
| EPS (Basic) | -$0.39 | +63.9% |
| EPS (Diluted) | -$0.39 | +63.9% |
| Total Liabilities |
| $287.7M |
| -14.6% |
| Stockholders' Equity | $218.8M | +7.9% |